Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage, primarily focusing on umbilical cord blood stem cells. This report covers the quarterly period ended February 28, 2007. The company operates facilities in Oldsmar, Florida, and Safti-Cell in Arizona, and holds licensing agreements in international markets including India, Mexico, and Central America.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Revenue | $4,173,702 | $3,691,253 |
| Net (Loss) Income | $(786,662) | $55,528 |
| Operating Loss | $(866,274) | $(111,680) |
| Cash and Cash Equivalents | $5,740,957 | $8,966,963 (End of Period) |
| Net Cash Used in Operating Activities | $(1,271,822) | $683,423 (Provided) |
| Cost of Sales Margin | 36% | 33% |
| Stockholders' Deficit | $(2,782,998) | $(2,092,146) |
Debt and Liquidity: The company maintains no indebtedness as of April 16, 2007. Total current liabilities were $5,798,235, primarily consisting of deferred revenue ($3,551,302). The company holds $1,052,221 in marketable securities and other investments.
Material Changes vs. Prior Period
- Profitability Reversal: The company shifted from a net income of $55,528 in Q1 2006 to a net loss of $786,662 in Q1 2007. This was driven by a 32% increase in marketing, general, and administrative expenses and a 25% increase in cost of sales, which outpaced a 13% revenue increase.
- Expense Drivers: Marketing expenses rose by approximately $815,000 due to strategic initiatives to increase market share. Research and development expenses surged to $133,564 from $11,620, related to proprietary technology for placental stem cells.
- Accounting Changes: The adoption of SFAS 123R (Share-Based Payment) on December 1, 2006, resulted in an additional $55,320 in stock-based compensation expense for the quarter.
- Cash Flow: Operating cash flow turned negative, using $1.27 million, compared to providing $683,000 in the prior year. This was attributed to the implementation of in-house financing plans for clients and payments of prior year accounts payable.
Guidance, Outlook, and Risks
- Strategic Delays: The company has indefinitely postponed the commercial launch of its Plureon fetal placental stem cell service due to technological commercialization considerations. Further development is required before new commercialization plans can be announced.
- Liquidity Outlook: Management anticipates that current cash, marketable securities, and operating cash flows will be sufficient to fund needs for the next 12 to 18 months. Capital expenditures for the fiscal year 2007 are anticipated to be approximately $500,000.
- Legal Proceedings: The company is involved in ongoing patent litigation with PharmaStem Therapeutics, Inc. regarding stem cell patents. While a final judgment was entered in Cryo-Cell's favor in the Delaware district court, PharmaStem has appealed to the Federal Circuit. Proceedings in related Florida cases are stayed pending the appeal.
- Revenue Sharing Agreements (RSAs): Interest expense includes payments to RSA partners based on storage revenue. As storage revenues increase in covered states (NY, TX, FL, IL), interest expense is expected to rise.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $1.27 million quarterly operating cash outflow given the indefinite delay in new revenue streams (Plureon).
- Legal Exposure: Monitor the status of the PharmaStem appeal at the Federal Circuit, as a reversal could impact future operations or require royalty payments.
- Revenue Quality: Assess the impact of the new in-house financing plans on accounts receivable aging and future cash collection cycles.
- Stock Compensation: Review the impact of SFAS 123R on future earnings, noting $379,000 of unrecognized compensation cost remaining to be recognized over 2.1 years.
- Deferred Revenue: Confirm the stability of the $9.7 million in total deferred revenue, which represents a significant portion of the company's liabilities and future revenue recognition.